Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2004-06-21

AUTHORS

Sergio Schwartzman, Roy Fleischmann, G James Morgan

ABSTRACT

Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA--infliximab, etanercept, and adalimumab--have been designed to modify the biologic effects of TNF. Infliximab and adalimumab are monoclonal antibodies, and etanercept is a soluble protein. The pharmacokinetic and pharmacodynamic properties of each differs significantly from those of the others. All three agents are effective and safe, and can improve the quality of life in patients with RA. Although no direct comparisons are available, clinical trials provide evidence that can be used to evaluate the comparative efficacy of these agents. Infliximab, in combination with methotrexate, has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, prevent joint erosions and joint-space narrowing, and improve physical function for up to 2 years. Etanercept has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, and slow the rate of joint destruction, and might improve physical function. Etanercept is approved with and without methotrexate for patients who have demonstrated an incomplete response to therapy with methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs), as well as for first-line therapy in early RA, psoriatic arthritis, and juvenile RA. Adalimumab relieves the signs and symptoms of RA with and without methotrexate and other DMARDs, decreases total joint score progression, prevents joint erosions and joint-space narrowing in combination with methotrexate, and might improve physical function. When selecting a TNF antagonist, rheumatologists should weigh evidence and experience with specific agents before a decision is made for use in therapy. More... »

PAGES

s3-s11

References to SciGraph publications

  • 2002-03-27. How does infliximab work in rheumatoid arthritis? in ARTHRITIS RESEARCH & THERAPY
  • 2002-05-09. Epidemiology and genetics of rheumatoid arthritis in ARTHRITIS RESEARCH & THERAPY
  • 1994-12. The Costs of Rheumatoid Arthritis in PHARMACOECONOMICS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/ar1013

    DOI

    http://dx.doi.org/10.1186/ar1013

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1051489549

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/15228615


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Arthritis, Rheumatoid", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Necrosis Factor-alpha", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Hospital for Special Surgery, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.239915.5", 
              "name": [
                "Hospital for Special Surgery, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Schwartzman", 
            "givenName": "Sergio", 
            "id": "sg:person.014133305773.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Texas Southwestern Medical Center, Dallas, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.267313.2", 
              "name": [
                "University of Texas Southwestern Medical Center, Dallas, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fleischmann", 
            "givenName": "Roy", 
            "id": "sg:person.01065106031.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065106031.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA", 
              "id": "http://www.grid.ac/institutes/grid.413480.a", 
              "name": [
                "Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Morgan", 
            "givenName": "G James", 
            "id": "sg:person.016267004752.30", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016267004752.30"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.2165/00019053-199406060-00005", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020626855", 
              "https://doi.org/10.2165/00019053-199406060-00005"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/ar578", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050495934", 
              "https://doi.org/10.1186/ar578"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/ar549", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004017405", 
              "https://doi.org/10.1186/ar549"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2004-06-21", 
        "datePublishedReg": "2004-06-21", 
        "description": "Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA--infliximab, etanercept, and adalimumab--have been designed to modify the biologic effects of TNF. Infliximab and adalimumab are monoclonal antibodies, and etanercept is a soluble protein. The pharmacokinetic and pharmacodynamic properties of each differs significantly from those of the others. All three agents are effective and safe, and can improve the quality of life in patients with RA. Although no direct comparisons are available, clinical trials provide evidence that can be used to evaluate the comparative efficacy of these agents. Infliximab, in combination with methotrexate, has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, prevent joint erosions and joint-space narrowing, and improve physical function for up to 2 years. Etanercept has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, and slow the rate of joint destruction, and might improve physical function. Etanercept is approved with and without methotrexate for patients who have demonstrated an incomplete response to therapy with methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs), as well as for first-line therapy in early RA, psoriatic arthritis, and juvenile RA. Adalimumab relieves the signs and symptoms of RA with and without methotrexate and other DMARDs, decreases total joint score progression, prevents joint erosions and joint-space narrowing in combination with methotrexate, and might improve physical function. When selecting a TNF antagonist, rheumatologists should weigh evidence and experience with specific agents before a decision is made for use in therapy.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/ar1013", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1297499", 
            "issn": [
              "1478-6354", 
              "1478-6362"
            ], 
            "name": "Arthritis Research & Therapy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "Suppl 2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "6"
          }
        ], 
        "keywords": [
          "disease-modifying anti-rheumatic drugs", 
          "symptoms of RA", 
          "joint-space narrowing", 
          "rheumatoid arthritis", 
          "physical function", 
          "score progression", 
          "joint erosions", 
          "first-line therapy", 
          "anti-TNF agents", 
          "anti-rheumatic drugs", 
          "early rheumatoid arthritis", 
          "necrosis factor antagonists", 
          "quality of life", 
          "joint destruction", 
          "psoriatic arthritis", 
          "TNF antagonists", 
          "clinical trials", 
          "factor antagonists", 
          "incomplete response", 
          "equal efficacy", 
          "pharmacodynamic properties", 
          "etanercept", 
          "comparative efficacy", 
          "biologic effects", 
          "infliximab", 
          "adalimumab", 
          "arthritis", 
          "patients", 
          "monoclonal antibodies", 
          "specific agents", 
          "methotrexate", 
          "therapy", 
          "symptoms", 
          "progression", 
          "antagonist", 
          "signs", 
          "efficacy", 
          "agents", 
          "narrowing", 
          "rheumatologists", 
          "TNF", 
          "trials", 
          "antibodies", 
          "evidence", 
          "drugs", 
          "outcomes", 
          "direct comparison", 
          "function", 
          "years", 
          "response", 
          "combination", 
          "destruction", 
          "life", 
          "protein", 
          "rate", 
          "effect", 
          "experience", 
          "use", 
          "differs", 
          "soluble proteins", 
          "quality", 
          "comparison", 
          "erosion", 
          "USA", 
          "decisions", 
          "properties", 
          "decrease total joint score progression", 
          "total joint score progression", 
          "joint score progression"
        ], 
        "name": "Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?", 
        "pagination": "s3-s11", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1051489549"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/ar1013"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "15228615"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/ar1013", 
          "https://app.dimensions.ai/details/publication/pub.1051489549"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:14", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_392.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/ar1013"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/ar1013'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/ar1013'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/ar1013'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/ar1013'


     

    This table displays all metadata directly associated to this object as RDF triples.

    187 TRIPLES      22 PREDICATES      104 URIs      93 LITERALS      13 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/ar1013 schema:about N00995a9bdadc46de857c36f3306bd4ce
    2 N0a343937ee674a61af3e0e6ab974bca4
    3 N3c0067608772457d893b6b38d2195e53
    4 N674273911a0949758e0e88317dfe7729
    5 N8c2d421c9aeb4350878b072fb9350d9e
    6 Ne94a0c854fc94ab99eb836f7e67fff6a
    7 anzsrc-for:11
    8 anzsrc-for:1103
    9 schema:author N96afaf31fcba49b09d98691843832114
    10 schema:citation sg:pub.10.1186/ar549
    11 sg:pub.10.1186/ar578
    12 sg:pub.10.2165/00019053-199406060-00005
    13 schema:datePublished 2004-06-21
    14 schema:datePublishedReg 2004-06-21
    15 schema:description Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA--infliximab, etanercept, and adalimumab--have been designed to modify the biologic effects of TNF. Infliximab and adalimumab are monoclonal antibodies, and etanercept is a soluble protein. The pharmacokinetic and pharmacodynamic properties of each differs significantly from those of the others. All three agents are effective and safe, and can improve the quality of life in patients with RA. Although no direct comparisons are available, clinical trials provide evidence that can be used to evaluate the comparative efficacy of these agents. Infliximab, in combination with methotrexate, has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, prevent joint erosions and joint-space narrowing, and improve physical function for up to 2 years. Etanercept has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, and slow the rate of joint destruction, and might improve physical function. Etanercept is approved with and without methotrexate for patients who have demonstrated an incomplete response to therapy with methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs), as well as for first-line therapy in early RA, psoriatic arthritis, and juvenile RA. Adalimumab relieves the signs and symptoms of RA with and without methotrexate and other DMARDs, decreases total joint score progression, prevents joint erosions and joint-space narrowing in combination with methotrexate, and might improve physical function. When selecting a TNF antagonist, rheumatologists should weigh evidence and experience with specific agents before a decision is made for use in therapy.
    16 schema:genre article
    17 schema:inLanguage en
    18 schema:isAccessibleForFree true
    19 schema:isPartOf N6d5ad2707ac240b7895773f3d8213418
    20 N72896728f86b4e6e9d6e87caf2c3cc2b
    21 sg:journal.1297499
    22 schema:keywords TNF
    23 TNF antagonists
    24 USA
    25 adalimumab
    26 agents
    27 antagonist
    28 anti-TNF agents
    29 anti-rheumatic drugs
    30 antibodies
    31 arthritis
    32 biologic effects
    33 clinical trials
    34 combination
    35 comparative efficacy
    36 comparison
    37 decisions
    38 decrease total joint score progression
    39 destruction
    40 differs
    41 direct comparison
    42 disease-modifying anti-rheumatic drugs
    43 drugs
    44 early rheumatoid arthritis
    45 effect
    46 efficacy
    47 equal efficacy
    48 erosion
    49 etanercept
    50 evidence
    51 experience
    52 factor antagonists
    53 first-line therapy
    54 function
    55 incomplete response
    56 infliximab
    57 joint destruction
    58 joint erosions
    59 joint score progression
    60 joint-space narrowing
    61 life
    62 methotrexate
    63 monoclonal antibodies
    64 narrowing
    65 necrosis factor antagonists
    66 outcomes
    67 patients
    68 pharmacodynamic properties
    69 physical function
    70 progression
    71 properties
    72 protein
    73 psoriatic arthritis
    74 quality
    75 quality of life
    76 rate
    77 response
    78 rheumatoid arthritis
    79 rheumatologists
    80 score progression
    81 signs
    82 soluble proteins
    83 specific agents
    84 symptoms
    85 symptoms of RA
    86 therapy
    87 total joint score progression
    88 trials
    89 use
    90 years
    91 schema:name Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
    92 schema:pagination s3-s11
    93 schema:productId N4a1ce274457f41eabfcd51bae18f40d8
    94 N60e87b7513aa431c8fcea44fa84c22d6
    95 Nefe186cb7fc34a6e8cfee755d8ed0ae9
    96 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051489549
    97 https://doi.org/10.1186/ar1013
    98 schema:sdDatePublished 2022-01-01T18:14
    99 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    100 schema:sdPublisher N99cda2ac6a08451fa3f7498441775f42
    101 schema:url https://doi.org/10.1186/ar1013
    102 sgo:license sg:explorer/license/
    103 sgo:sdDataset articles
    104 rdf:type schema:ScholarlyArticle
    105 N00995a9bdadc46de857c36f3306bd4ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    106 schema:name Tumor Necrosis Factor-alpha
    107 rdf:type schema:DefinedTerm
    108 N0a343937ee674a61af3e0e6ab974bca4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name Animals
    110 rdf:type schema:DefinedTerm
    111 N3c0067608772457d893b6b38d2195e53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Humans
    113 rdf:type schema:DefinedTerm
    114 N4a1ce274457f41eabfcd51bae18f40d8 schema:name dimensions_id
    115 schema:value pub.1051489549
    116 rdf:type schema:PropertyValue
    117 N60e87b7513aa431c8fcea44fa84c22d6 schema:name pubmed_id
    118 schema:value 15228615
    119 rdf:type schema:PropertyValue
    120 N674273911a0949758e0e88317dfe7729 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Antibodies, Monoclonal
    122 rdf:type schema:DefinedTerm
    123 N6d5ad2707ac240b7895773f3d8213418 schema:volumeNumber 6
    124 rdf:type schema:PublicationVolume
    125 N72896728f86b4e6e9d6e87caf2c3cc2b schema:issueNumber Suppl 2
    126 rdf:type schema:PublicationIssue
    127 N797243ebc4ad44dbadc9fbecadf507b0 rdf:first sg:person.01065106031.43
    128 rdf:rest N9c07ca5b6bc9433486d880a75e5941d6
    129 N8c2d421c9aeb4350878b072fb9350d9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    130 schema:name Treatment Outcome
    131 rdf:type schema:DefinedTerm
    132 N96afaf31fcba49b09d98691843832114 rdf:first sg:person.014133305773.18
    133 rdf:rest N797243ebc4ad44dbadc9fbecadf507b0
    134 N99cda2ac6a08451fa3f7498441775f42 schema:name Springer Nature - SN SciGraph project
    135 rdf:type schema:Organization
    136 N9c07ca5b6bc9433486d880a75e5941d6 rdf:first sg:person.016267004752.30
    137 rdf:rest rdf:nil
    138 Ne94a0c854fc94ab99eb836f7e67fff6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Arthritis, Rheumatoid
    140 rdf:type schema:DefinedTerm
    141 Nefe186cb7fc34a6e8cfee755d8ed0ae9 schema:name doi
    142 schema:value 10.1186/ar1013
    143 rdf:type schema:PropertyValue
    144 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    145 schema:name Medical and Health Sciences
    146 rdf:type schema:DefinedTerm
    147 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    148 schema:name Clinical Sciences
    149 rdf:type schema:DefinedTerm
    150 sg:journal.1297499 schema:issn 1478-6354
    151 1478-6362
    152 schema:name Arthritis Research & Therapy
    153 schema:publisher Springer Nature
    154 rdf:type schema:Periodical
    155 sg:person.01065106031.43 schema:affiliation grid-institutes:grid.267313.2
    156 schema:familyName Fleischmann
    157 schema:givenName Roy
    158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065106031.43
    159 rdf:type schema:Person
    160 sg:person.014133305773.18 schema:affiliation grid-institutes:grid.239915.5
    161 schema:familyName Schwartzman
    162 schema:givenName Sergio
    163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18
    164 rdf:type schema:Person
    165 sg:person.016267004752.30 schema:affiliation grid-institutes:grid.413480.a
    166 schema:familyName Morgan
    167 schema:givenName G James
    168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016267004752.30
    169 rdf:type schema:Person
    170 sg:pub.10.1186/ar549 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004017405
    171 https://doi.org/10.1186/ar549
    172 rdf:type schema:CreativeWork
    173 sg:pub.10.1186/ar578 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050495934
    174 https://doi.org/10.1186/ar578
    175 rdf:type schema:CreativeWork
    176 sg:pub.10.2165/00019053-199406060-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020626855
    177 https://doi.org/10.2165/00019053-199406060-00005
    178 rdf:type schema:CreativeWork
    179 grid-institutes:grid.239915.5 schema:alternateName Hospital for Special Surgery, New York, NY, USA
    180 schema:name Hospital for Special Surgery, New York, NY, USA
    181 rdf:type schema:Organization
    182 grid-institutes:grid.267313.2 schema:alternateName University of Texas Southwestern Medical Center, Dallas, TX, USA
    183 schema:name University of Texas Southwestern Medical Center, Dallas, TX, USA
    184 rdf:type schema:Organization
    185 grid-institutes:grid.413480.a schema:alternateName Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
    186 schema:name Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
    187 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...